Status and phase
Conditions
Treatments
About
The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb14045 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Diagnosis of 1 of the following diseases:
Patients with relapsed or refractory disease with no available standard therapy
ECOG performance status 0-2
Not a candidate for, or refusing treatment with hematopoietic stem cell transplantation
Fertile patients must agree to use effective contraception during and for 4 weeks after the last dose of XmAb14045
Male patients must agree to use highly effective contraception, and refrain from donating sperm during the treatment period and for at least 4 weeks after the last dose of XmAb14045
Able and willing to complete the entire study
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
120 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal